Immunogen as well as preparation method and application thereof

By fusing the RBP gene with the core antigen of hepatitis B to form a multimer, the problem of insufficient RBP immunogenicity in the prior art is solved, and the early diagnosis ability of liver and kidney diseases is significantly improved.

CN119019570APending Publication Date: 2024-11-26SHANGHAI JIEMEN BIO TECH
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411147586.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

In the prior art, when retinol-binding protein (RBP) is an immunogen, the immune response is weak, resulting in a generally low antiserum titer, making it difficult to effectively use it for early diagnosis of liver and kidney diseases.

Method used

By constructing the vector protein and inserting the RBP gene, adding a linking sequence to fuse the target protein with the hepatitis B core antigen to form a homologous multimer, using the powerful B cell sensitization and antigen presentation ability of the hepatitis B core antigen to improve the immunogen of the RBP antigen sex.

Benefits of technology

The immunogenicity was significantly improved, and the pass rate of serum antibodies reached 70%, which greatly improved the early diagnosis ability of liver and kidney diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019570A_ABST
    Figure CN119019570A_ABST
Patent Text Reader

Abstract

The invention discloses an immunogen as well as a preparation method and application thereof. The immunogen is a fusion protein and is obtained by adding a connecting sequence to carry out fusion expression on three amino acid sites, namely 21 and 22, 79 and 80, 130 and 131 of a hepatitis B carrier protein with a nucleotide sequence shown as SEQ ID No.2. The amino acid sequence of the immunogen is as shown in SEQ ID No. 4. The immunogen forms a homologous multimer by using the main assembly characteristic of the hepatitis B core antigen, so that the RBP antigens are orderly displayed on the surface of the hepatitis B core antigen multimer, and the immunogenicity of the target protein can be greatly improved. Therefore, the percent of pass of the immunogen serum antibody prepared by the invention is 70% and is far higher than that of a recombinant retinol binding protein monomer, and the immunogen serum antibody has good immunogenicity and is more beneficial to early diagnosis of liver and kidney diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of in vitro diagnostic reagents, and in particular to an immunogen and a preparation method and application thereof. Background Art

[0002] Retinol binding protein (RBP) is a small molecular weight vitamin transport protein, which is synthesized in the liver and has a molecular weight of 21KD. In the body, RBP is responsible for transporting retinol from liver cells to body tissues and cells. In the blood, RBP combines with prealbumin (PA) and retinol to form a macromolecular complex, which cannot pass through the glomerulus and thus exists in human blood; when the complex reaches the target cells, retinol is absorbed by the target cells, and RBP dissociates into a small molecular weight free state, which can be filtered through the glomerulus, enter the renal tubules, be absorbed by epithelial cells, and be converted into amino acids for reuse by the body. The remaining very small part of RBP is not absorbed and is directly excreted from the body with urine.

[0003] Clinically, the levels of serum RBP and urine RBP can be used as effective detection indicators for liver and kidney damage as well as other syndromes such as diabetes. RBP is synthesized in the liver. If the liver's synthesis function is impaired, the concentration of serum RBP will decrease, and the degree of decrease is highly correlated with the degree of liver damage. Since RBP has a short half-life and sensitive reactions, it is more suitable as an indicator of early liver damage. Retinol binding protein is metabolized in the kidneys, so the level of urine RBP is of great significance for the early diagnosis of kidney disease.

[0004] At present, the latex enhanced immunoturbidimetry method is mostly used in the market to determine RBP. The specific implementation schemes include polyantibody method, double monoclonal antibody method, monoclonal antibody and polyantibody combination method, etc. Among these methods, the polyantibody method is the most widely used. The immunogen in the preparation of polyantibodies mainly comes from genetic recombination expression. Due to its small molecular weight, conservative genes, and high homology between different species, it has relatively weak immunogenicity when immunizing animals, and cannot stimulate the receptor to produce a strong immune response, making the titer of antiserum generally low. Summary of the invention

[0005] In order to solve the problems in the prior art, the present invention provides an immunogen and a preparation method and application thereof.

[0006] In order to achieve the above-mentioned invention object, the present invention adopts the following technical solutions:

[0007] The present invention provides an immunogen, which comprises a carrier protein and an RBP gene inserted into the carrier protein.

[0008] Furthermore, the nucleotide sequence of the carrier protein is shown in SEQ ID No.2.

[0009] Furthermore, the nucleotide sequence of the RBP gene is shown in SEQ ID No.1.

[0010] The present invention also provides a method for preparing the immunogen, which specifically comprises: connecting the RBP gene to three amino acid sites at positions 21 and 22, 79 and 80, and 130 and 131 of the carrier protein through a connecting sequence, and constructing an expression vector; transforming competent cells with the expression vector, purifying and expressing, and obtaining the immunogen.

[0011] Furthermore, the amino acid sequence of the carrier protein is shown in SEQ ID No.3.

[0012] Furthermore, the connecting sequence is: (EAAAK)n, (GGGGS)n, (GGGGSGGGGT)n, where n is 1-4.

[0013] Furthermore, the amino acid sequence of the immunogen is shown in SEQ ID No.4.

[0014] Furthermore, the temperature of the purification expression is 15°C-20°C.

[0015] Furthermore, the purification expression temperature is 20°C.

[0016] The present invention also provides a multimer, which is composed of the immunogen.

[0017] The present invention also provides the use of the immunogen in preparing a detection reagent and a kit for diagnosing kidney disease.

[0018] The present invention also provides the use of the immunogen in preparing a vaccine for preventing hepatitis B infection.

[0019] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0020] The present invention mainly solves the problems existing in the existing antibody preparation by constructing a fusion protein. Specifically, a linker sequence is added to fuse the target protein with the hepatitis B core antigen for expression, and then the main assembly characteristics of the hepatitis B core antigen are used to form a homopolymer, so that the RBP antigen is orderly displayed on the surface of the hepatitis B core antigen polymer. This polymerization can greatly improve the immunogenicity of the target protein, and at the same time, with the help of the powerful B cell sensitization ability, antigen presentation and Th cell activation ability of the hepatitis B core antigen, the immunogenicity of the fusion protein is further enhanced. Therefore, the qualified rate of the immunogenic serum antibody prepared by the present invention is 70%, which is much higher than the recombinant retinol binding protein monomer, has good immunogenicity, and is more conducive to the early diagnosis of liver and kidney diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1A roadmap for the construction of immune antigens.

[0022] Figure 2 This is the electrophoresis diagram of the purified fusion protein. DETAILED DESCRIPTION

[0023] The technical solution of the present invention is further described in detail with reference to the following specific examples.

[0024] In the following examples, unless otherwise specified, the experimental methods used are all conventional methods, and the materials and reagents used can be purchased from biological or chemical reagent companies.

[0025] Example 1

[0026] This example mainly experiments and verifies the target gene insertion site, connection sequence screening, expression conditions and purification process. The details are as follows:

[0027] 1. Antigen preparation

[0028] (1) The present invention uses an E. coli expression system. The following genes are synthesized and constructed into expression vectors.

[0029] RBP gene sequence:

[0030] GAGCGCGACTGCCGAGTGAGCAGCTTCCGAGTCAAGGAGAACTTCGACAAGGCTCGCTTCTCTGGGACCTGGTACGCCATGGCCAAGAAGGACCCCGAGGGCCTCTTTCTGCAGGACAACATCGTCGCGGAGTTCTCCGTGGACGAGACCGGCCAGATGAGCGCCACAGCCAAGGGCCGAGTCCGTCTTTTGAATAACTGGGACGTGTGCGCAGACATGGTGGGCACCTTCACAGACACCGAGGACCCTGCCAAGTTCAAGATGAAGTACTGGGGCGTAGCCTCCTTTCTCCAGAAAGGAAATGATGACCACTGGATCGTCGACACAGACTACGACACGTATGCCGTGCAGTACTCCTGCCGCCTCCTGAACCTCGATGGCACCTGTGCTGACAGCTACTCCTTCGTGTTTTCCCGGGACCCCAACGGCCTGCCCCCAGAAGCGCAGAAGATTGTAAGGCAGCGGCAGGAGGAGCTGTGCCTGGCCAGGCAGTACAGGCTGATCGTCCACAACGGTTACTGCGATGGCAGATCAGAAAGAAACCTTTTGTAG(SEQ ID No.1)

[0031] Carrier protein gene sequence:

[0032] (SEQ ID No.2)

[0033] The present invention optimizes the fusion site of the exogenous protein in the core antigen by analyzing the quaternary structure of the protein. The amino acid sequence of the core antigen is shown in SEQ ID No.3, and the exogenous gene fusion expression is performed at three amino acid sites, 21 and 22, 79 and 80, 130 and 131 of the amino acid sequence. Specifically, the RBP gene is inserted into one of the above three sites of the hepatitis B core antigen (the amino acid sequence is shown in SEQ ID No.3) to obtain a fusion protein.

[0034] Building ideas such as Figure 1 As shown, the linker sequence is: (EAAAK)n, (GGGGS)n, (GGGGSGGGGT)n, and n is 1-4. The specific construction method is: double restriction digestion (Not I / Xho I) is performed using Pet28a plasmid, and the fusion protein (including core antigen + linker + RBP exogenous insertion fragment) is digested with designed restriction sites at both ends and then connected to the plasmid to construct an expression vector. The amino acid sequence of the fusion protein is shown in SEQ ID No.4.

[0035] (2) Protein expression and purification

[0036] The expression vector constructed above was transformed into E. coli competent cells BL21 (DE3), and the positive transformants were selected for expression verification. The qualified strains were expanded and maintained.

[0037] Optimization of expression conditions: The preserved strains were inoculated into LB medium containing kanamycin resistance and inoculated at an inoculum volume of 1% (V / V). Cultured at 37°C and 160rpm. When OD600 reached about 1.0, the seed solution was inoculated into TB medium, and cultured at 37°C until OD600 reached about 2.0. The culture temperature was adjusted to 30°C, 25°C, 20°C and 15°C for self-induction culture. After 16 hours of shaking culture at 200rpm, the bacteria were collected by centrifugation at 4000rpm. Take the same amount of wet bacteria and resuspend them in 10 times the volume of PBS. After ultrasonic cell disruption under ice bath conditions, centrifuge at 8000rpm to collect the supernatant and precipitate. The precipitate was resuspended with an equal volume of PBS, and both the supernatant and the precipitate were analyzed by SDS-PAGE. The results showed that the soluble expression of the target protein at a temperature of 15°C accounted for the largest proportion, followed by 20°C, and the rest was mainly expressed in inclusion bodies. However, in terms of absolute expression, 20°C is better than 15°C. Therefore, the expression condition was 20°C.

[0038] The expression product at 20°C was purified. First, ammonium sulfate graded precipitation was performed, and the saturation of ammonium sulfate was 15%, 20%, 25% and 30% respectively. The results showed that after ammonium sulfate graded precipitation, the target protein was mainly present in the 25% ammonium sulfate precipitate after 20% ammonium sulfate treatment. The corresponding ammonium sulfate precipitate was resuspended with PBS with 1 / 2 wet weight of the bacteria, centrifuged at 12000rpm, and the supernatant was collected. After filtering with a 0.45μm filter membrane, column chromatography was used for purification to collect the target protein. Figure 2 As shown, the target protein with a purity of more than 95%, namely, the fusion protein, was finally obtained.

[0039] 2. Animal immunization

[0040] The antigen used was recombinant retinol binding protein monomer and compared with the above prepared fusion protein. The protein purity was over 90%. The specific activity of the active protein detected by the kit was 70%±5%. The antigen information is shown in Table 1.

[0041] Table 1 Basic information of immunogen

[0042] name source Label purity Remark Control Antigen Yeast expression HIS×6 >90% monomer Experimental Antigen E. coli expression none >90% HBcAg fusion

[0043] Five-month-old New Zealand white rabbits were used for the experiment. The experimental animals were observed for one week before immunization to ensure that there were no abnormalities in their diet and daily life before subsequent experiments.

[0044] Immunization regimen:

[0045] The antigen was diluted to 2 mg / ml with PBS and mixed with Freund's complete adjuvant in equal proportions (volume), and emulsified at 18000 rpm with a homogenizer for 5 minutes. After emulsification, carefully drip it into the standing cold water and observe the changes in the emulsion within 10 minutes. If it does not spread, the emulsification is complete, otherwise the emulsification time needs to be extended until the emulsification is complete. This emulsion was used to immunize rabbits at multiple points on the back subcutaneously at a dose of 0.5 ml / rabbit. The preparation method of the subsequent booster immunization emulsion was the same, except that Freund's complete adjuvant was changed to Freund's incomplete adjuvant. The immunization dose and site were the same. Animal serum titer detection was performed from the second booster immunization. Seven days after the booster immunization, about 0.5 ml of blood from the rabbit's ear vein was drawn. It was placed at 4°C overnight, centrifuged at 4000g for 5 minutes, and the serum was collected. The serum was gradiently diluted with physiological saline, and after punching a 1% agarose gel plate, a specific concentration of antigen, specifically 100 μg / ml, was added to the middle wells, and gradient dilutions of antiserum were added to the peripheral wells in sequence. After the liquid has penetrated the gel, place the gel plate in a wet box and react at 37°C for 16 hours. Observe the precipitation line after the reaction between antigen and antibody.

[0046] The titer test results are shown in Table 2. The results show that the titer is not less than 1:16 and is considered qualified. After the fourth booster immunization, the serum antibody qualification rates of the control group and the experimental group were 22% and 70%, respectively. After the T test, the difference between the two groups was extremely significant (Table 3), indicating that the fusion protein has stronger immunogenicity.

[0047] Table 2 Agarose immunoassay titer test results

[0048]

[0049]

[0050] Table 3 T test results

[0051] t Degrees of Freedom Sig.(double tail) Mean Difference Standard error difference Assume equal variances -2.959 17 0.009 -11.06667 3.74005 Equal variances are not assumed -3.053 13.942 0.009 -11.06667 3.62461

[0052] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for a person skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to replace some of the technical features therein by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions claimed to be protected by the present invention.

[0053] Sequence Listing

[0054] SEQ ID No.1RBP gene sequence

[0055] GAGCGCGACTGCCGAGTGAGCAGCTTCCGAGTCAAGGAGAACTTCGACA

[0056] AGGCTCGCTTCTCTGGGACCTGGTACGCCATGGCCAAGAAGGACCCCGAG

[0057] GGCCTCTTTCTGCAGGACAACATCGTCGCGGAGTTCTCCGTGGACGAGAC

[0058] CGGCCAGATGAGCGCCACAGCCAAGGGCCGAGTCCGTCTTTTGAATAACT

[0059] GGGACGTGTGCGCAGACATGGTGGGCACCTTCACAGACACCGAGGACCCT

[0060] GCCAAGTTCAAGATGAAGTACTGGGGCGTAGCCTCCTTTCTCCAGAAAGG

[0061] AAATGATGACCACTGGATCGTCGACACAGACTACGACACGTATGCCGTGC

[0062] AGTACTCCTGCCGCCTCCTGAACCTCGATGGCACCTGTGCTGACAGCTACT

[0063] CCTTCGTGTTTTCCCGGGACCCCAACGGCCTGCCCCCAGAAGCGCAGAAG

[0064] ATTGTAAGGCAGCGGCAGGAGGAGCTGTGCCTGGCCAGGCAGTACAGGC

[0065] TGATCGTCCACAACGGTTACTGCGATGGCAGATCAGAAAGAAACCTTTTG

[0066] TAGSEQ ID No.2 vector protein gene sequence

[0067] ATGGATATCGATCCTTATAAAGAATTCGGAGCTACTGTGGAGTTACTCTCG

[0068] TTTCTCCCGAGTGACTTCTTTCCTTCAGTACGAGATCTTCTGGATACCGCC

[0069] AGCGCGCTGTATCGGGAAGCCTTGGAGTCTCCTGAGCACTGCAGCCCTCA

[0070] CCATACTGCCCTCAGGCAAGCAATTCTTTGCTGGGGGGAGCTCATGACTCT

[0071] GGCCACGTGGGTGGGTGTTAACTTGGAAGATCCAGCTAGCAGGGACCTGG

[0072] TAGTCAGTTATGTCAACACTAATATGGGTTTAAAGTTCAGGCAACTCTTGT

[0073] GGTTTCACATTAGCTGCCTCACTTTCGGCCGAGAAACAGTTCTAGAATATT

[0074] TGGTGTCTTTCGGAGTGTGGATCCGCACTCCTCCAGCTTATAGGCCTCCGA

[0075] ATGCCCCTATCCTGTCGACACTCCCGGAGACTACTGTTGTTAGACGTCGAG

[0076] GCAGGTCACCTAGAAGAAGAACTCCTTCGCCTCGCAGGCGAAGGTCTCAA

[0077] TCGCCGCGGCGCCGAAGATCTCAATCTCGGGAATCTCAATGTTAGSEQ ID No.3 core antigen

[0078] MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTA

[0079] LRQAILCWGELMTLATWVGVNLEDPASRDLVVSYVNTNMGLKFRQLLWFHI

[0080] SCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVSEQ ID No.4 After fusion, MDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDGGGGSGGGGTERDCRVSSFRVKENFDKARFSGTWYAMAKKDPEGLFLQDNIVAEFSVDETGQMSATAKGRVRLLNNWDVCADMVGTFTDTEDPAKFKMKYWGVASFLQKGNDDHWIVDTDYDTYAVQYSCRLLNLDGTCADSYSFVFSRDPNGLPPEAQKIVRQRQEELCLARQYRLIVHNGYCDGRSERNLLGGGGSGGGGSRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVV*

Claims

1. An immunogen, characterized in that It comprises a carrier protein and an RBP gene inserted into the carrier protein.

2. The immunogen according to claim 1, characterized in that The nucleotide sequence of the carrier protein is shown in SEQ ID No.

2.

3. The immunogen according to claim 1, characterized in that The nucleotide sequence of the RBP gene is shown in SEQ ID No.

1.

4. The method for preparing an immunogen according to claim 1, characterized in that: The preparation method comprises the following steps: connecting the RBP gene to the amino acid site of the carrier protein via a connecting sequence, and constructing an expression vector; transforming competent cells with the expression vector, and obtaining the immunogen through purification and expression.

5. The preparation method according to claim 4, characterized in that: The amino acid sites are respectively positions 21 and 22, 79 and 80, 130 and 131 of the amino acid sequence of the carrier protein; the amino acid sequence of the carrier protein is shown in SEQ ID No.

3.

6. The preparation method according to claim 4, characterized in that: The connecting sequences are: (EAAAK)n, (GGGGS)n, (GGGGSGGGGT)n, where n is 1-4.

7. The preparation method according to claim 4, characterized in that: The temperature for the purification expression is 15°C-20°C.

8. A polymer, characterized in that The multimer consists of the immunogen according to claim 1.

9. Use of the immunogen according to claim 1 in the preparation of detection reagents and kits for diagnosing kidney disease.

10. Use of the immunogen according to claim 1 in the preparation of a vaccine for preventing hepatitis B infection.

Citation Information

Patent Citations

  • Immunity-enhanced type virus-like particle for presenting recombinant cat sensitinogen rFel d 1 protein, expression vector of immunity-enhanced type virus-like particle and preparation and application of mmunity-enhanced type virus-like particle

    CN105219742A

  • Protein complex and preparation method thereof

    CN118165123A

  • Fusion protein comprising albumin and retinol-binding protein

    US20160200796A1